Literature DB >> 16707533

EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).

W Zhang1, M Doherty, E Pascual, T Bardin, V Barskova, P Conaghan, J Gerster, J Jacobs, B Leeb, F Lioté, G McCarthy, P Netter, G Nuki, F Perez-Ruiz, A Pignone, J Pimentão, L Punzi, E Roddy, T Uhlig, I Zimmermann-Gòrska.   

Abstract

OBJECTIVE: To develop evidence based recommendations for the diagnosis of gout.
METHODS: The multidisciplinary guideline development group comprised 19 rheumatologists and one evidence based medicine expert, representing 13 European countries. Ten key propositions regarding diagnosis were generated using a Delphi consensus approach. Research evidence was searched systematically for each proposition. Wherever possible the sensitivity, specificity, likelihood ratio (LR), and incremental cost-effectiveness ratio were calculated for diagnostic tests. Relative risk and odds ratios were estimated for risk factors and co-morbidities associated with gout. The quality of evidence was categorised according to the evidence hierarchy. The strength of recommendation (SOR) was assessed using the EULAR visual analogue and ordinal scales.
RESULTS: 10 key propositions were generated though three Delphi rounds including diagnostic topics in clinical manifestations, urate crystal identification, biochemical tests, radiographs, and risk factors/co-morbidities. Urate crystal identification varies according to symptoms and observer skill but is very likely to be positive in symptomatic gout (LR = 567 (95% confidence interval (CI), 35.5 to 9053)). Classic podagra and presence of tophi have the highest clinical diagnostic value for gout (LR = 30.64 (95% CI, 20.51 to 45.77), and LR = 39.95 (21.06 to 75.79), respectively). Hyperuricaemia is a major risk factor for gout and may be a useful diagnostic marker when defined by the normal range of the local population (LR = 9.74 (7.45 to 12.72)), although some gouty patients may have normal serum uric acid concentrations at the time of investigation. Radiographs have little role in diagnosis, though in late or severe gout radiographic changes of asymmetrical swelling (LR = 4.13 (2.97 to 5.74)) and subcortical cysts without erosion (LR = 6.39 (3.00 to 13.57)) may be useful to differentiate chronic gout from other joint conditions. In addition, risk factors (sex, diuretics, purine-rich foods, alcohol, lead) and co-morbidities (cardiovascular diseases, hypertension, diabetes, obesity, and chronic renal failure) are associated with gout. SOR for each proposition varied according to both the research evidence and expert opinion.
CONCLUSIONS: 10 key recommendations for diagnosis of gout were developed using a combination of research based evidence and expert consensus. The evidence for diagnostic tests, risk factors, and co-morbidities was evaluated and the strength of recommendation was provided.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16707533      PMCID: PMC1798330          DOI: 10.1136/ard.2006.055251

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  47 in total

1.  Gout. Easy to misdiagnose.

Authors:  R D Sturrock
Journal:  BMJ       Date:  2000-01-15

Review 2.  Diagnosis of crystal-induced arthritis by synovial fluid examination for crystals: lessons from an imperfect test.

Authors:  J B Segal; D Albert
Journal:  Arthritis Care Res       Date:  1999-12

3.  Letter: Nomogram for Bayes theorem.

Authors:  T J Fagan
Journal:  N Engl J Med       Date:  1975-07-31       Impact factor: 91.245

Review 4.  Diagnostic tests 4: likelihood ratios.

Authors:  Jonathan J Deeks; Douglas G Altman
Journal:  BMJ       Date:  2004-07-17

5.  Definitive diagnosis of gout by identification of urate crystals in asymptomatic metatarsophalangeal joints.

Authors:  C A Agudelo; A Weinberger; H R Schumacher; R Turner; J Molina
Journal:  Arthritis Rheum       Date:  1979-05

6.  Synovial fluid analysis for diagnosis of intercritical gout.

Authors:  E Pascual; E Batlle-Gualda; A Martínez; J Rosas; P Vela
Journal:  Ann Intern Med       Date:  1999-11-16       Impact factor: 25.391

7.  A prospective study of gout in New Zealand Maoris.

Authors:  G W Brauer; I A Prior
Journal:  Ann Rheum Dis       Date:  1978-10       Impact factor: 19.103

8.  Community based epidemiological study on hyperuricemia and gout in Kin-Hu, Kinmen.

Authors:  K C Lin; H Y Lin; P Chou
Journal:  J Rheumatol       Date:  2000-04       Impact factor: 4.666

9.  Effect of low level lead exposure on hyperuricemia and gout among middle aged and elderly men: the normative aging study.

Authors:  N A Shadick; R Kim; S Weiss; M H Liang; D Sparrow; H Hu
Journal:  J Rheumatol       Date:  2000-07       Impact factor: 4.666

10.  Preliminary criteria for the classification of the acute arthritis of primary gout.

Authors:  S L Wallace; H Robinson; A T Masi; J L Decker; D J McCarty; T F Yü
Journal:  Arthritis Rheum       Date:  1977-04
View more
  144 in total

Review 1.  International position paper on febuxostat.

Authors:  Tim L Jansen; Pascal Richette; Fernando Perez-Ruiz; Anne-Kathrin Tausche; Philip-André Guerne; Leonardo Punzi; Burkhard Leeb; Victoria Barskova; Till Uhlig; José Pimentão; Irena Zimmermann-Górska; Elisio Pascual; Thomas Bardin; Michael Doherty
Journal:  Clin Rheumatol       Date:  2010-04-17       Impact factor: 2.980

2.  Quality of care in patients with gout: why is management suboptimal and what can be done about it?

Authors:  N Lawrence Edwards
Journal:  Curr Rheumatol Rep       Date:  2011-04       Impact factor: 4.592

3.  Culture-sensitive adaptation and validation of the community-oriented program for the control of rheumatic diseases methodology for rheumatic disease in Latin American indigenous populations.

Authors:  Ingris Peláez-Ballestas; Ysabel Granados; Adriana Silvestre; José Alvarez-Nemegyei; Evart Valls; Rosana Quintana; Yemina Figuera; Flor Julian Santiago; Mario Goñi; Rosa González; Natalia Santana; Romina Nieto; Irais Brito; Imelda García; Maria Cecilia Barrios; Manuel Marcano; Adalberto Loyola-Sánchez; Ivan Stekman; Marisa Jorfen; Maria Victoria Goycochea-Robles; Fadua Midauar; Rosa Chacón; Maria Celeste Martin; Bernardo A Pons-Estel
Journal:  Rheumatol Int       Date:  2014-03-29       Impact factor: 2.631

4.  Prioritizing Future Research on Allopurinol and Febuxostat for the Management of Gout: Value of Information Analysis.

Authors:  Eric Jutkowitz; Fernando Alarid-Escudero; Hyon K Choi; Karen M Kuntz; Hawre Jalal
Journal:  Pharmacoeconomics       Date:  2017-10       Impact factor: 4.981

5.  As compared to allopurinol, urate-lowering therapy with febuxostat has superior effects on oxidative stress and pulse wave velocity in patients with severe chronic tophaceous gout.

Authors:  A-K Tausche; M Christoph; M Forkmann; U Richter; S Kopprasch; C Bielitz; M Aringer; C Wunderlich
Journal:  Rheumatol Int       Date:  2013-09-12       Impact factor: 2.631

Review 6.  Gout - a guide for the general and acute physicians.

Authors:  Abhishek Abhishek; Edward Roddy; Michael Doherty
Journal:  Clin Med (Lond)       Date:  2017-02       Impact factor: 2.659

7.  International survey on the diagnosis and management of gout.

Authors:  M Doherty; T Bardin; E Pascual
Journal:  Ann Rheum Dis       Date:  2007-12       Impact factor: 19.103

Review 8.  Development of minimum standards of care for juvenile localized scleroderma.

Authors:  Tamás Constantin; Ivan Foeldvari; Clare E Pain; Annamária Pálinkás; Peter Höger; Monika Moll; Dana Nemkova; Lisa Weibel; Melinda Laczkovszki; Philip Clements; Kathryn S Torok
Journal:  Eur J Pediatr       Date:  2018-05-04       Impact factor: 3.183

Review 9.  Treatment Options for Gout.

Authors:  Bettina Engel; Johannes Just; Markus Bleckwenn; Klaus Weckbecker
Journal:  Dtsch Arztebl Int       Date:  2017-03-31       Impact factor: 5.594

10.  Goals of gout treatment: a patient perspective.

Authors:  Jasvinder A Singh
Journal:  Clin Rheumatol       Date:  2018-08-04       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.